GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » EPS without NRI

Aprea Therapeutics (Aprea Therapeutics) EPS without NRI : $-3.33 (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics EPS without NRI?

Aprea Therapeutics's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.68. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.33.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 57.10% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 32.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Aprea Therapeutics's EPS without NRI or its related term are showing as below:

APRE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30.2   Med: 12.2   Max: 57.1
Current: 57.1

During the past 7 years, Aprea Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 57.10% per year. The lowest was -30.20% per year. And the median was 12.20% per year.

APRE's 3-Year EPS without NRI Growth Rate is ranked better than
93.99% of 1298 companies
in the Biotechnology industry
Industry Median: 5.15 vs APRE: 57.10

Aprea Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.67. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.32.

Aprea Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.67. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.32.


Aprea Therapeutics EPS without NRI Historical Data

The historical data trend for Aprea Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprea Therapeutics EPS without NRI Chart

Aprea Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -97.83 -49.77 -35.18 -22.28 -3.94

Aprea Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.34 -0.89 -0.86 -0.90 -0.68

Competitive Comparison of Aprea Therapeutics's EPS without NRI

For the Biotechnology subindustry, Aprea Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aprea Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Aprea Therapeutics's PE Ratio without NRI falls into.



Aprea Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aprea Therapeutics  (NAS:APRE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Aprea Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Aprea Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Aprea Therapeutics (Aprea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Executives
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
John P. Hamill officer: SrVP/CFO/Prin. Fin &Acctg. Off 4092 NEW HOPE ROAD, FURLONG PA 18925
Michael Grissinger director C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Marc Duey director 27 STRATHMORE ROAD, NATICK MA 01760
Oren Gilad officer: President, CEO 535 BOYLSTON STREET, BOSTON MA 02116
Rifat Pamukcu director 535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade director, officer: President & CEO MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar officer: SVP, Chief Medical Officer 535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel officer: Chief Business Officer 535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen officer: SVP, Chief Scientific Officer 535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
5am Ventures Iv, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Aprea Therapeutics (Aprea Therapeutics) Headlines

From GuruFocus

Aprea Therapeutics Appoints John Hamill as Chief Financial Officer

By Stock market mentor Stock market mentor 01-30-2023